Publications by authors named "B Jarzab"
Differentiated thyroid carcinoma (DTC) in children is uncommon; clinical presentation over recent decades is incompletely characterized. This retrospective cohort study analyzed demographic and disease characteristics of consecutive juveniles with DTC treated from 1970 to 2015 at Poland's largest pediatric DTC referral center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, who had available records. Sex, age, histopathological characteristics, and DTC stage were documented.
View Article and Find Full Text PDFAdvances in the diagnosis and treatment of adrenocortical carcinoma (ACC), along with the development of new therapeutic and diagnostic methods, have prompted a team of experts to formulate the first Polish guidelines for managing ACC. This article presents the diagnostic and therapeutic recommendations resulting from the discussion of specialists from various medical specialities, who participated in a series of online meetings aimed at developing consistent and effective recommendations under the National Oncology Strategy. These guidelines aim to optimise ACC treatment in Poland through coordinated efforts of multidisciplinary specialist teams, ensuring an effective and modern approach.
View Article and Find Full Text PDFArticle Synopsis
- Nintedanib is a drug being tested for effectiveness against advanced thyroid cancers, specifically radioiodine refractory differentiated thyroid cancer (RAIR DTC) and medullary thyroid cancer (MTC), in a phase II clinical trial (EORTC-1209).
- The study compared nintedanib with a placebo for its effects on progression-free survival (PFS) among patients, showing a median PFS of 3.7 months for nintedanib vs. 2.9 months for placebo in the RAIR DTC cohort, although no objective responses were noted in either group.
- Adverse effects were more common in the nintedanib group, with about
Article Synopsis
- Lenvatinib and sorafenib are common first-line treatments for advanced thyroid cancer that doesn't respond to iodine therapy, but many patients become resistant to these drugs.
- The COSMIC-311 phase 3 study found that cabozantinib provided significant clinical benefits for patients who progressed on previous treatments, showing better progression-free survival (PFS) and response rates compared to placebo.
- The study involved 258 patients with various thyroid cancer histologies, revealing 16.6 months of median PFS for cabozantinib versus just 3.2 months for placebo in those who had previously used sorafenib, indicating cabozantinib's effectiveness.
Although thyroid cancer (TC) is generally associated with a favourable prognosis, there are certain high-risk groups with a clear unmet therapeutic need. Unravelling the genomic landscape of TC has recently led to the development of novel effective targeted treatments. To date, these treatments have mostly been evaluated in non-randomised single-arm phase II clinical trials and are consequently non-reimbursed in several countries.
View Article and Find Full Text PDF